Press Releases
May 25, 2023

Data at meeting illustrate company's progress in addressing unmet needs in a broad range of hard-to-treat solid tumors and hematologic malignancies TOKYO, May 25, 2023 /PRNewswire/ -- Astellas...

May 25, 2023

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has committed to supporting the 3rd phase of the Global Health Innovative Technology Fund...

May 16, 2023

- Conduct collaborative research on Sony's unique polymeric materials to achieve high-DAR ADC - TOKYO, May 16, 2023 /PRNewswire/ -- Sony Corporation (President and CEO: Kimio Maki, "Sony") and...

EXPLORE ALL US PRESS RELEASES

Articles
May 5, 2023

As a global pharmaceutical company, Astellas takes the fight against cancer personally and is deeply committed to our employees and customers who are a part of the oncology community. Fifty...

Apr 25, 2023

Astellas Executive Vice President and Head of Medical Affairs Shontelle Dodson and Vice President, Head of Biopharma Development Marci English were recently featured in an Axios Smart Brevity...

Apr 4, 2023

Astellas provides biopharma industry experience for PharmD students When Astellas learned that the Chicago State University College of Pharmacy did not offer a biopharma industry rotation as part...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products